| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H32O6 |
| Molecular Weight | 416.5073 |
| Optical Activity | UNSPECIFIED |
| Additional Stereochemistry | Yes |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | AXIAL, R |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(OC)=C2C(C[C@H](C)[C@H](C)CC3=CC(OC)=C(OC)C(OC)=C23)=C1
InChI
InChIKey=JEJFTTRHGBKKEI-OKILXGFUSA-N
InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+
| Molecular Formula | C24H32O6 |
| Molecular Weight | 416.5073 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Schisandrin A is a bioactive lignan occurring in the fruits of plants of the Schisandra genus that have traditionally been used in Korea for treating various inflammatory diseases. Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway. Schisandrin A represents a potential antiviral agent to block DENV replication in vitro and in vivo. Schisandrin A has been widely reported as being very effective for the treatment of liver disease. The hepatoprotective mechanisms of schisandrin A may include activation of autophagy flux and inhibition of apoptosis.
Approval Year
PubMed
Patents
Sample Use Guides
Male Sprague-Dawley rats were intragastrically administered with varied doses of Schisandrin A (8 mg/kg or 16 mg/kg or 32 mg/kg) or 75 mg/kg ketoconazole for three consecutive days.
Route of Administration:
Intragastric
